Poliovirus capsid protein epitope

The Poliovirus capsid protein epitope refers to regions on the surface of the poliovirus capsid proteins (VP1, VP2, VP3, and VP4) recognized by the host immune system, especially neutralizing antibodies and T cells. Among these, the VP1 protein contains a well-defined neutralizing epitope located at amino acid residues 93–104, which is a major site recognized both by neutralizing monoclonal antibodies (such as C3) and by immune sera. These epitopes play a critical role in the development of immune-based therapies and vaccines: they are the main targets for protective immunity, as they mediate antibody neutralization and T-cell responses. Epitopes on all four capsid proteins have been shown to be recognized by the immune system, contributing to both B-cell (antibody) and T-cell (helper T lymphocyte) mediated immunity. As such, they are considered primary molecular targets for vaccine design and serologic testing, and are a focus of viral evolution in response to immune pressure (antigenic drift/escape). No classical drug molecules (e.g., small molecules) are known to bind specifically to these epitopes, but many vaccines are designed to induce antibodies against them. The key challenge is that variation in these epitopes may allow immune escape, underscoring their importance in both continued surveillance and vaccine update efforts.

Other names

Poliovirus capsid epitopePoliovirus VP1 epitopePoliovirus neutralization epitopePoliovirus antigenic site

Induction of virus neutralization by antibodies (for vaccines/antibody therapeutics); T-cell mediated immune recognition (for cellular immunity)